NEW YORK: Pfizer reported a jump in second-quarter profits on Thursday behind a near doubling of revenues driven by sales of its COVID-19 vaccine and therapeutic drug Paxlovid.
US officials last month approved emergency authorisation to Pfizer and Moderna for COVID-19 vaccines in under-five-year-olds, the final age group awaiting immunisation in most countries.
Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut: